At this point none of the other antiviral drugs have shown effectiveness in patients with moderate to severe Covid 19 eg Remdesivir, Regeneron's covid antibiotic,Ritonavir Molnupiravir,, or convalescent serum.
IPIX is reported to be its reviewing the Phase 2 trial data as well as the compassionate use data. We should know the results of this review soon. Even if the review shows no benefit in hospitalized patients with moderate to severe Covid it does not mean Brilacidin will not be an effective treatment for Covid19.
Did the other companies give up when they failed in their trials for hospitalized patients with moderate to severe Covid?
No, they tried to find their niche in the treatment of Covid. Do the other drugs have better in vitro results or a better safety profile than Brilacidin. In my opinion they do not. How many have potential Covid 19 antiviral drugs have a Selectivity index better than 146?
Omicron's rapid spread and multiple mutations represents a serious progression in the Coronavirus pandemic. Even though Omicron is reported to be less deadly, its high rate of contagion, even in the triple vaccinated, has the potential to have severe effects on the economy and society at large.
Unless you live in a bunker you should be scared of the Cornavirus pandemic, including current and future mutations.
We should all pray the research being done on therapeutics produces effective treatments.
The NIH is obviously concerned about the continuing Corona virus pandemic. It has dedicated substantial funding to therapeutic research including the ACTIV trials.
IPIX has mentioned the ACTIV trial as a future goal for Brilacidin research which is looking for repurposed drugs with anticovid activity.
The ACTIV trial currently is studying drugs including Ivermectin, Fluvoxamine and Fluticasone at 49 locations.
"Complete analysis of trial results already has begun, with the aim to potentially identify positive trends in the data that could support Brilacidin for inclusion in larger COVID-19 platform trials, such as the U.K.’s CTAP program and the NIH’s ACTIV program. The purpose of these programs is to prioritize development of promising COVID-19 therapeutics"
Of course other possibilities for advancement of Brilacidin for Covid 19 exist. Further review of the Phase 2 study and compassionate use may result in the FDA approving a phase 3 study; especially in the setting of persistent Covid infections, the shortcomings of vaccinations, and the development of future mutations.
Another possibility is a clinical trial combining Remdesivir and Brilacidin to take advantage of their synergistic antiviral effects.
IMO the current situation with the development of Omicron, the certainty of future mutations and their effects on the economy, geopolitics, education, childhood development and many other aspects of our society, the chance of Brilacidin's inclusion in the ACTIV trial is much higher today.
GLTA, Farrell
Pardon the inclusion of parts of previous posts in this post
.
